INVEGA SUSTENNA
Total Payments
$20.6M
Transactions
215,713
Doctors
29,967
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.4M | 40,874 | 11,267 |
| 2023 | $4.7M | 41,567 | 11,196 |
| 2022 | $3.8M | 38,909 | 10,418 |
| 2021 | $2.7M | 32,023 | 9,931 |
| 2020 | $811,998 | 9,048 | 3,225 |
| 2019 | $1.9M | 18,595 | 5,560 |
| 2018 | $552,198 | 18,258 | 5,311 |
| 2017 | $666,934 | 16,439 | 4,649 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9.4M | 4,606 | 45.7% |
| Food and Beverage | $5.0M | 204,296 | 24.4% |
| Unspecified | $4.0M | 45 | 19.4% |
| Travel and Lodging | $1.6M | 5,309 | 7.8% |
| Consulting Fee | $439,352 | 182 | 2.1% |
| Education | $99,256 | 1,259 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $11,300 | 15 | 0.1% |
| Gift | $4.99 | 1 | 0.0% |
Payments by Type
General
$16.6M
215,668 transactions
Research
$4.0M
45 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Antipsychotic Utilization, Treatment Patterns, Healthcare Resource Use, and Costs among Medicare Beneficiaries with Schizophrenia in the United States (PALM-1035) | Janssen Scientific Affairs, LLC | $3.2M | 0 |
| Impact of paliperidone palmitate on clinical, economic, and psychosocial outcomes in patients with schizophrenia from a health system perspective | Janssen Scientific Affairs, LLC | $267,154 | 0 |
| Proposal to Evaluate the Societal Outcomes and Costs of Care of Patients Receiving Treatment at Community Social Services | Janssen Scientific Affairs, LLC | $100,252 | 0 |
| County of Summit Alcohol Drug Addiction And Mental Health Services Societal Outcomes and Costs of Care of Patients Receiving Treatment at Community Social Services | Janssen Scientific Affairs, LLC | $63,045 | 0 |
| A concierge model of customized adherence enhancement (CAE) plus long-actinginjectable antipsychotic (CAL-Concierge) in individuals with schizophrenia at risk fortreatment non-adherence and for homelessness | Janssen Research & Development, LLC | $13,055 | 0 |
Top Doctors Receiving Payments for INVEGA SUSTENNA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, NY | $4.0M | 86 |
| , MD | Psychiatry | Saint Louis, MO | $590,317 | 555 |
| Sanford Herman | Psychiatry | Jamaica, NY | $586,860 | 670 |
| , MD | Psychiatry | Durham, NC | $498,771 | 505 |
| , MD | Psychiatry | Pittsburgh, PA | $444,850 | 528 |
| , M.D | Psychiatry | Costa Mesa, CA | $375,018 | 402 |
| , PA-C | Physician Assistant | Sacramento, CA | $337,205 | 439 |
| , DNP, CRNP, FNP-BC | Registered Nurse | Allentown, PA | $331,815 | 306 |
| , M.D | Psychiatry | Bronx, NY | $314,836 | 412 |
| , MD | Psychiatry | Las Vegas, NV | $297,583 | 600 |
| , MD | Psychiatry | Pittsburgh, PA | $296,478 | 457 |
| , M.D | Psychiatry | Glen Allen, VA | $285,530 | 340 |
| , M.D | Psychiatry | Irvine, CA | $280,111 | 335 |
| , M.D | Psychiatry | Santa Cruz, CA | $267,443 | 383 |
| , PMHNP-BC | Psychiatric/Mental Health | Maitland, FL | $265,439 | 272 |
| , M.D | Psychiatry | San Diego, CA | $234,105 | 221 |
| , M.D | Psychiatry | Pensacola, FL | $218,858 | 302 |
| , M.D | Psychiatry | Visalia, CA | $196,851 | 213 |
| , M.D | Internal Medicine | Hickory, NC | $188,059 | 263 |
| , PMHNP | Psychiatric/Mental Health | Terre Haute, IN | $187,939 | 298 |
| , M.D | Addiction Psychiatry | Syracuse, NY | $181,640 | 371 |
| , M.D | Psychiatry | Scottsdale, AZ | $169,841 | 240 |
| , D.O | Psychiatry | East Saint Louis, IL | $167,940 | 295 |
| , MD | Psychiatry | Corinth, MS | $166,885 | 227 |
| , M.D | Psychiatry | Duluth, GA | $163,018 | 240 |
Ad
Manufacturing Companies
- Janssen Pharmaceuticals, Inc $16.5M
- Janssen Scientific Affairs, LLC $4.1M
- Janssen Research & Development, LLC $13,055
- Johnson & Johnson Health Care Systems Inc. $11,009
- Janssen Biotech, Inc. $432.18
- Johnson & Johnson Surgical Vision, Inc. $224.37
- Ethicon US, LLC $45.80
Product Information
- Type Drug
- Total Payments $20.6M
- Total Doctors 29,967
- Transactions 215,713
About INVEGA SUSTENNA
INVEGA SUSTENNA is a drug associated with $20.6M in payments to 29,967 healthcare providers, recorded across 215,713 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Pharmaceuticals, Inc.
Payment data is available from 2017 to 2024. In 2024, $5.4M was paid across 40,874 transactions to 11,267 doctors.
The most common payment nature for INVEGA SUSTENNA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($9.4M, 45.7% of total).
INVEGA SUSTENNA is associated with 5 research studies, including "Antipsychotic Utilization, Treatment Patterns, Healthcare Resource Use, and Costs among Medicare Beneficiaries with Schizophrenia in the United States (PALM-1035)" ($3.2M).